Glen Eagle Advisors’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$339 Buy
+5
New +$125 ﹤0.01% 1069
2025
Q3
– Sell
-17
Closed -$208 – 1123
2025
Q2
$208 Hold
17
– – ﹤0.01% 1015
2025
Q1
$244 Hold
17
– – ﹤0.01% 1029
2024
Q4
$271 Hold
17
– – ﹤0.01% 1053
2024
Q3
$409 Hold
17
– – ﹤0.01% 1079
2024
Q2
$339 Hold
17
– – ﹤0.01% 1083
2024
Q1
$338 Hold
17
– – ﹤0.01% 1045
2023
Q4
$381 Hold
17
– – ﹤0.01% 980
2023
Q3
$344 Hold
17
– – ﹤0.01% 983
2023
Q2
$435 Sell
17
-3
-15% -$79 ﹤0.01% 1010
2023
Q1
$595 Buy
20
+3
+18% +$87 ﹤0.01% 993
2022
Q4
$460 Hold
17
– – ﹤0.01% 1089
2022
Q3
$370 Hold
17
– – ﹤0.01% 1037
2022
Q2
$465 Hold
17
– – ﹤0.01% 946
2022
Q1
$570 Hold
17
– – ﹤0.01% 899
2021
Q4
$589 Hold
17
– – ﹤0.01% 883
2021
Q3
$530 Hold
17
– – ﹤0.01% 1013
2021
Q2
$618 Hold
17
– – ﹤0.01% 991
2021
Q1
$744 Hold
17
– – ﹤0.01% 953
2020
Q4
$780 Hold
17
– – ﹤0.01% 921
2020
Q3
$565 Buy
+17
New +$543 ﹤0.01% 876

Other funds holding AVNS

Glen Eagle Advisors's AVNS Position: Q3 2026 in Review

Glen Eagle Advisors opened a new position in Avanos Medical (AVNS) in Q3 2026: 5 shares worth $339. The stake represents ﹤0.01% of the portfolio and ranks #1069 among its holdings. This is a return to the name: Glen Eagle Advisors previously reported a position in AVNS as recently as Q2 2025.

Glen Eagle Advisors first reported a position in AVNS in Q3 2020 and has held it in 21 quarters since. The position peaked at $780 in Q4 2020. 4 funds tracked by Wall St. Rank hold AVNS as of Q3 2026.

  • Glen Eagle Advisors held 5 shares of Avanos Medical worth $339 as of Q3 2026.
  • Avanos Medical was a new Glen Eagle Advisors position in Q3 2026.
  • Avanos Medical made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q3 2026, its #1069 holding.
  • Glen Eagle Advisors first reported a position in Avanos Medical in Q3 2020 and has held it in 21 quarters since.
  • Glen Eagle Advisors's Avanos Medical position peaked at $780 in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Avanos Medical as of Q3 2026.

Based on Glen Eagle Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.